Novo Nordisk AS (MEX:NOVOBN) Forward Dividend Yield %: 5.46% (As of Jun. 24, 2026)


MEX:NOVOBN Novo Nordisk AS MEX:NOVOBN
79 GF Score
Price MXN810.00
GF Value MXN2,387.36
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Novo Nordisk AS Forward Dividend Yield %?

Novo Nordisk AS MEX:NOVOBN +3.85% 79 Forward Dividend Yield % is 5.46% as of Jun. 24, 2026. GuruFocus rates MEX:NOVOBN with a GF Score™ of 79/100 and a GF Value™ of MXN2,387.36 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 503 Drug Manufacturers companies, Novo Nordisk AS ranks better than 87.67% on this metric.

As of today (2026-06-24), the Forward Annual Dividend Yield of Novo Nordisk AS is 5.46%.

As of today (2026-06-24), the Trailing Annual Dividend Yield of Novo Nordisk AS is 4.09%.

MEX:NOVOBN's Forward Dividend Yield % is ranked better than
87.67% of 503 companies
in the Drug Manufacturers industry
Industry Median: 2.1 vs MEX:NOVOBN: 5.46

Novo Nordisk AS's Dividends per Share for the three months ended in Mar. 2026 was MXN22.17.

During the past 12 months, Novo Nordisk AS's average Dividends Per Share Growth Rate was 2.60% per year. During the past 3 years, the average Dividends Per Share Growth Rate was 27.80% per year. During the past 5 years, the average Dividends Per Share Growth Rate was 23.80% per year. During the past 10 years, the average Dividends Per Share Growth Rate was 12.90% per year.

During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Novo Nordisk AS was 37.70% per year. The lowest was -30.80% per year. And the median was 15.80% per year.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Novo Nordisk AS  (MEX:NOVOBN) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Novo Nordisk AS Forward Dividend Yield % Related Terms


MEX:NOVOBN vs LLY, JNJ, ABBV: Forward Dividend Yield % Comparison

For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk AS Forward Dividend Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Novo Nordisk AS's Forward Dividend Yield % falls into.


MEX:NOVOBN
79GF Score
Novo Nordisk AS MEX:NOVOBN
Forward Dividend Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novo Nordisk AS Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Novo Nordisk AS Recent Full-Year* Dividend History

Amount Ex-date Record Date Pay Date Type Frequency Forex Rate
DKK 7.9500002026-03-302026-03-302026-03-31Cash Dividendsemi-annuallyDKK:MXN 2.778609
DKK 3.7500002025-08-182025-08-182025-08-19Cash Dividendsemi-annuallyDKK:MXN 2.928489

* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.

Novo Nordisk AS's Forward Annual Dividend Yield (%) for Today is calculated as

Forward Annual Dividend Yield=Forward Full Year Dividend/Current Share Price
=44.1798831/810.00
=5.45 %

Current Share Price is MXN810.00.
Novo Nordisk AS's Dividends per Share for the forward twelve months is calculated as MXN22.08994155 * 2 = MXN44.1798831.

Novo Nordisk AS's Trailing Annual Dividend Yield (%) for Today is calculated as

Trailing Annual Dividend Yield=Most Recent Full Year Dividend/Current Share Price
=33.0717753/810.00
=4.08 %

Current Share Price is MXN810.00.
Novo Nordisk AS's Dividends per Share for the trailing twelve months (TTM) ended in Today is MXN33.0717753.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Forward Dividend Yield % of 5.46% mean?
Novo Nordisk AS (MEX:NOVOBN) has a Forward Dividend Yield % of 5.46% as of Jun. 24, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Novo Nordisk AS and its competitors. According to the industry distribution chart, Novo Nordisk AS ranks #62 out of 503 companies in the Drug Manufacturers industry, placing it in the top 12.3%.
Is Novo Nordisk AS's Forward Dividend Yield % too high?
Novo Nordisk AS's current Forward Dividend Yield % is 5.46%. The Drug Manufacturers industry median Forward Dividend Yield % is 2.10. Novo Nordisk AS's value of 5.46% is 160% above this industry median. Based on the distribution chart, Novo Nordisk AS ranks #62 out of 503 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Novo Nordisk AS has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's Forward Dividend Yield % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Novo Nordisk AS ranks #62 out of 503 companies for Forward Dividend Yield %. This places Novo Nordisk AS in the top 12% of its industry — outperforming the majority of peers. The industry median Forward Dividend Yield % is 2.10. Novo Nordisk AS's value of 5.46% is 160% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.10, based on 503 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novo Nordisk AS's current Forward Dividend Yield % of 5.46% is 160% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Novo Nordisk AS and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novo Nordisk AS's current Forward Dividend Yield % is 5.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (MEX:NOVOBN) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN2,387.36, compared to a current price of MXN810.00 — trading 66.1% below its estimated fair value. The current Forward Dividend Yield % is 5.46% and 160% above the Drug Manufacturers industry median of 2.10. Novo Nordisk AS's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Novo Nordisk AS (MEX:NOVOBN), the current Forward Dividend Yield % is 5.46% as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novo Nordisk AS (MEX:NOVOBN) Overvalued in 2026?

Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued. The current stock price of MXN810.00 is trading 66.1% below its estimated GF Value™ of MXN2,387.36. GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.

Key valuation signals for MEX:NOVOBN:

  • Forward Dividend Yield %: 5.46%
  • GF Value™: MXN2,387.36 vs. price of MXN810.00 (66.1% below fair value)
  • GF Score™: 79/100 with 4 warning signs
  • Industry Position: 160% above the Drug Manufacturers median (#62 of 503)

No single metric tells the full story. See the MEX:NOVOBN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novo Nordisk AS Business Description

Address Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
79GF Score

Get the complete analysis for MEX:NOVOBN

Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN810.00
Price
MXN2,387.36
GF Value